JP6814745B2 - ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 - Google Patents
ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 Download PDFInfo
- Publication number
- JP6814745B2 JP6814745B2 JP2017555779A JP2017555779A JP6814745B2 JP 6814745 B2 JP6814745 B2 JP 6814745B2 JP 2017555779 A JP2017555779 A JP 2017555779A JP 2017555779 A JP2017555779 A JP 2017555779A JP 6814745 B2 JP6814745 B2 JP 6814745B2
- Authority
- JP
- Japan
- Prior art keywords
- percent
- cells
- agent
- less
- aliquot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153475P | 2015-04-27 | 2015-04-27 | |
| US62/153,475 | 2015-04-27 | ||
| PCT/US2016/029510 WO2016176299A1 (en) | 2015-04-27 | 2016-04-27 | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020200805A Division JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520638A JP2018520638A (ja) | 2018-08-02 |
| JP2018520638A5 JP2018520638A5 (https=) | 2019-07-04 |
| JP6814745B2 true JP6814745B2 (ja) | 2021-01-20 |
Family
ID=57198812
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
| JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 |
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 |
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10761086B2 (https=) |
| EP (2) | EP3289094B1 (https=) |
| JP (3) | JP6814745B2 (https=) |
| AU (2) | AU2016253957C1 (https=) |
| CA (1) | CA2983022C (https=) |
| WO (2) | WO2016176288A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| HK1213046A1 (zh) | 2012-09-19 | 2016-06-24 | Dana-Farber Cancer Institute, Inc. | 動態bh3分析 |
| CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| US10793915B2 (en) | 2015-01-12 | 2020-10-06 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| US11142554B2 (en) | 2015-03-18 | 2021-10-12 | Massachusetts Institute Of Technology | Selective Mcl-1 binding peptides |
| US9901574B2 (en) | 2015-04-20 | 2018-02-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| AU2016253957C1 (en) | 2015-04-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
| ES2739749T3 (es) | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
| WO2018017922A2 (en) | 2016-07-22 | 2018-01-25 | Massachusetts Institute Of Technology | Selective bfl-1 peptides |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| EP3852783A1 (en) * | 2018-09-17 | 2021-07-28 | Massachusetts Institute of Technology | Peptides selective for bcl-2 family proteins |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| JP7589159B2 (ja) * | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| WO2025212653A1 (en) * | 2024-04-01 | 2025-10-09 | Dana-Farber Cancer Institute, Inc. | Methods including bh3 profiling of car t cells |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| BR9610058A (pt) | 1995-07-28 | 1999-07-27 | Marie Curie Cancer Care | Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células |
| EP0799422A1 (en) | 1995-10-24 | 1997-10-08 | Sangstat Medical Corporation | Anti alpha-galactosyl screening technique |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1999014321A1 (en) | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| WO2000059526A1 (en) | 1999-04-07 | 2000-10-12 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| AU6906100A (en) | 1999-08-16 | 2001-03-13 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis |
| WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
| WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| WO2003040168A2 (en) | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
| WO2003055515A1 (en) | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| EP1608969A4 (en) | 2003-03-19 | 2007-06-06 | Alfa Wassermann Inc | SEPARATION AND ACCUMULATION OF SUB-CELLULAR COMPONENTS, AND PROTEINS WHICH ARE DRAWN THEREFROM |
| EP1997828B1 (en) | 2003-11-05 | 2017-10-04 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides from BCL-2 and uses thereof |
| US7714005B2 (en) | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
| JP2005130867A (ja) | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
| WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
| US20070027175A1 (en) | 2005-07-27 | 2007-02-01 | Shaughnessy John Jr | Antineoplastic activities of ellipticine and its derivatives |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
| KR100786759B1 (ko) | 2006-07-07 | 2007-12-18 | 김현기 | Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
| WO2008021484A2 (en) * | 2006-08-16 | 2008-02-21 | Eutropics Pharmaceuticals | Assay system to identify therapeutic agents |
| WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
| US8466140B2 (en) | 2007-09-10 | 2013-06-18 | University Of Massachusetts | Mitochondria-targeted anti-tumor agents |
| JP5783721B2 (ja) * | 2007-09-26 | 2015-09-24 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｂｃｌ−２ファミリーポリペプチドを調節する方法及び組成物 |
| JP2009240173A (ja) | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
| SG176801A1 (en) | 2009-06-11 | 2012-01-30 | Minerva Biotechnologies Corp | Methods for culturing stem and progenitor cells |
| WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
| KR102062416B1 (ko) * | 2012-05-10 | 2020-01-03 | 유트로픽스 파마슈티컬스, 인크. | 실용 가능한 암 진단 대체 법 |
| US20150322479A1 (en) | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
| HK1213046A1 (zh) * | 2012-09-19 | 2016-06-24 | Dana-Farber Cancer Institute, Inc. | 動態bh3分析 |
| JP6327662B2 (ja) | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| WO2015010094A1 (en) * | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
| CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| AU2016253957C1 (en) | 2015-04-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
| US11092602B2 (en) | 2015-07-06 | 2021-08-17 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
| JP7589159B2 (ja) | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
-
2016
- 2016-04-27 AU AU2016253957A patent/AU2016253957C1/en active Active
- 2016-04-27 EP EP16787045.0A patent/EP3289094B1/en active Active
- 2016-04-27 WO PCT/US2016/029495 patent/WO2016176288A1/en not_active Ceased
- 2016-04-27 CA CA2983022A patent/CA2983022C/en active Active
- 2016-04-27 JP JP2017555779A patent/JP6814745B2/ja active Active
- 2016-04-27 US US15/568,994 patent/US10761086B2/en active Active
- 2016-04-27 EP EP16787039.3A patent/EP3288964B1/en active Active
- 2016-04-27 WO PCT/US2016/029510 patent/WO2016176299A1/en not_active Ceased
- 2016-04-27 JP JP2017555780A patent/JP6802185B2/ja active Active
- 2016-04-27 AU AU2016255749A patent/AU2016255749B2/en active Active
- 2016-04-27 US US15/569,851 patent/US20180120297A1/en not_active Abandoned
-
2020
- 2020-07-27 US US16/939,736 patent/US11867688B2/en active Active
- 2020-12-03 JP JP2020200805A patent/JP2021036915A/ja not_active Withdrawn
-
2021
- 2021-02-26 US US17/186,344 patent/US20210255167A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2983022A1 (en) | 2016-11-03 |
| US11867688B2 (en) | 2024-01-09 |
| US10761086B2 (en) | 2020-09-01 |
| JP6802185B2 (ja) | 2020-12-16 |
| AU2016253957C1 (en) | 2021-04-01 |
| EP3289094B1 (en) | 2024-06-05 |
| US20180120297A1 (en) | 2018-05-03 |
| JP2018514210A (ja) | 2018-06-07 |
| US20210255167A1 (en) | 2021-08-19 |
| JP2021036915A (ja) | 2021-03-11 |
| US20210041419A1 (en) | 2021-02-11 |
| EP3288964A4 (en) | 2018-10-31 |
| JP2018520638A (ja) | 2018-08-02 |
| EP3289094A4 (en) | 2018-10-31 |
| AU2016253957A1 (en) | 2017-10-19 |
| HK1252055A1 (en) | 2019-05-10 |
| HK1252058A1 (en) | 2019-05-10 |
| WO2016176288A1 (en) | 2016-11-03 |
| EP3288964A1 (en) | 2018-03-07 |
| AU2016255749A1 (en) | 2017-10-19 |
| EP3288964B1 (en) | 2024-02-21 |
| WO2016176299A1 (en) | 2016-11-03 |
| AU2016255749B2 (en) | 2021-10-14 |
| CA2983022C (en) | 2023-03-07 |
| CA2983024A1 (en) | 2016-11-03 |
| AU2016253957B2 (en) | 2020-10-22 |
| EP3289094A1 (en) | 2018-03-07 |
| US20180128813A1 (en) | 2018-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6814745B2 (ja) | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 | |
| US12529692B2 (en) | Live cell imaging dynamic BH3 profiling | |
| Alam et al. | Characterization of liver-and cancer-type-organic anion transporting polypeptide (OATP) 1B3 messenger RNA expression in normal and cancerous human tissues | |
| CN107703109B (zh) | 二维硫化钼多肽复合材料及其在靶向cd47癌症标记中的应用 | |
| JP2005047895A (ja) | Ｈｃｖ調節タンパク質 | |
| Head et al. | Identification of small molecule-binding proteins in a native cellular environment by live-cell photoaffinity labeling | |
| KR20100074743A (ko) | 초고속 스크리닝용 단백질칩 시스템을 이용한 항체모방 펩타이드 탐색방법 | |
| US20040265917A1 (en) | Methods of measuring the ability of a test compound to inactivate a biological target in cells of a subject | |
| CA2983024C (en) | Compositions and methods for assessing toxicity using dynamic bh3 profiling | |
| HK1252055B (en) | Compositions and methods for assessing toxicity using dynamic bh3 profiling | |
| CN110100179A (zh) | 一种高通量免疫印迹分析的方法和装置 | |
| US11447550B2 (en) | Peptides for molecular detection of PD-L1 | |
| HK1252058B (en) | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells | |
| Hu | Development of HER2-Targeted Theranostics for Diagnosis and Treatment of Breast Cancer | |
| JP2012115195A (ja) | バセドウ病の検査方法、バセドウ病の予防薬または治療薬のスクリーニング方法、およびバセドウ病検査用のキット | |
| KR20140043418A (ko) | 벤조안트라센 오염 검출을 위한 마커 및 키트 | |
| HK1191096B (en) | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200706 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6814745 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |